Armodafinil is the R-enantiomer of modafinil, meaning one specific three-dimensional form of the wakefulness-promoting molecule. It was developed to retain the longer-lasting activity of that form. The page reviews clinical evidence for excessive sleepiness associated with narcolepsy, treated obstructive sleep apnea and shift work sleep disorder.
What Is Armodafinil?
Armodafinil is the single-enantiomer form of modafinil: specifically, the R-enantiomer, also called R-modafinil. Modafinil supplied as a conventional medicine is a racemic mixture containing approximately equal amounts of the R- and S-enantiomers. Enantiomers have the same chemical formula but differ in three-dimensional arrangement, and the two forms of modafinil have different pharmacokinetic profiles. Armodafinil was developed to retain the longer-lasting activity associated with the R-enantiomer while providing a more predictable exposure than the racemic mixture. The United States Food and Drug Administration approved armodafinil in 2007 under the brand name Nuvigil for excessive sleepiness associated with narcolepsy, treated obstructive sleep apnea, and shift work sleep disorder.
Armodafinil is generally described as having a longer half-life and a smoother concentration-time curve than racemic modafinil. The S-enantiomer is eliminated more rapidly, whereas the R-enantiomer persists for substantially longer; this distinction can produce greater late-day exposure after armodafinil administration. Armodafinil is not simply a stronger stimulant: its clinical effects are usually characterized as wakefulness promotion with comparatively less peripheral sympathomimetic stimulation than traditional amphetamine-type stimulants, although insomnia, anxiety, elevated heart rate, and blood-pressure changes can still occur. Its approved use is medical rather than general-purpose productivity enhancement, and evidence for use in healthy people is more limited than evidence in sleep-wake disorders.
Quick Reference
Member reference tables summarize the compound's research parameters.
Residual sleepiness in treated obstructive sleep apnea
Armodafinil is approved to improve wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea, alongside—not instead of—effective airway therapy.
Clinical trials support improved wakefulness and reduced daytime sleepiness in narcolepsy; it does not treat cataplexy directly.
Shift work disorder
Used before a work shift to promote wakefulness in people with excessive sleepiness related to shift work disorder.
Sustained Attention & Performance
Supported Research
Sleep-loss-related vigilance deficits
Wake-promoting agents in this class can improve alertness and performance measures during sleep restriction, but do not replace adequate sleep.
Executive function under fatigue
Benefits are generally most evident when sleepiness is present; effects in well-rested healthy adults are less consistent and not an approved indication.
Mood-Related Research
Emerging Evidence
Adjunctive bipolar depression studies
Trials have explored adjunctive armodafinil for bipolar depression, with mixed findings across studies and no general approval for this purpose.
Fatigue and motivation symptoms
Research interest exists in fatigue-related symptoms, but psychiatric activation, anxiety, and insomnia require particular clinical caution.
Mechanistic Findings
Preliminary Data
Dopamine transporter activity
Armodafinil inhibits dopamine transporter-mediated reuptake, contributing to wake-promoting effects; its full neural mechanism remains incompletely defined.
Longer exposure profile
As the R-enantiomer of modafinil, armodafinil has pharmacokinetic differences that may support later-day plasma concentrations in some users.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Prefer products obtained through a licensed pharmacy with an identifiable manufacturer, lot number, expiry date, and intact tamper-evident packaging.
Verified Marker
Lot-specific identity and potency testing
A credible certificate of analysis should identify armodafinil and report assay/potency for the specific lot, ideally using validated HPLC or equivalent methods.
Verified Marker
Third-party contaminant screening
Independent testing for heavy metals, microbial contamination, and relevant residual solvents provides stronger assurance than a vendor-only claim.
Acceptable Range
Accurate tablet or capsule strength
The dosage form should clearly state mg strength and excipients; the listed text specifies avoiding splitting modified or uncertain formulations without pharmacist guidance.
Quality Concern
Unverified “research” tablets or capsules
Products without traceable manufacturing, lot-specific testing, or regulated dispensing may be mislabeled, underdosed, contaminated, or substituted with another stimulant.
Modafinil for residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome Pack, A. I., Black, J. E., Schwartz, J. R. L., et al., 2001, American Journal of Respiratory and Critical Care Medicine
Armodafinil as adjunctive therapy for major depression associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study Calabrese, J. R., Ketter, T. A., Youakim, J. M., et al., 2010, American Journal of Psychiatry